BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 20026647)

  • 1. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane.
    Wängberg B; Khorram-Manesh A; Jansson S; Nilsson B; Nilsson O; Jakobsson CE; Lindstedt S; Odén A; Ahlman H
    Endocr Relat Cancer; 2010 Mar; 17(1):265-72. PubMed ID: 20026647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant mitotane treatment for adrenocortical carcinoma.
    Terzolo M; Angeli A; Fassnacht M; Daffara F; Tauchmanova L; Conton PA; Rossetto R; Buci L; Sperone P; Grossrubatscher E; Reimondo G; Bollito E; Papotti M; Saeger W; Hahner S; Koschker AC; Arvat E; Ambrosi B; Loli P; Lombardi G; Mannelli M; Bruzzi P; Mantero F; Allolio B; Dogliotti L; Berruti A
    N Engl J Med; 2007 Jun; 356(23):2372-80. PubMed ID: 17554118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].
    Lecka A; Ginalska-Malinowska M
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):234-6. PubMed ID: 17020662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly.
    Daffara F; De Francia S; Reimondo G; Zaggia B; Aroasio E; Porpiglia F; Volante M; Termine A; Di Carlo F; Dogliotti L; Angeli A; Berruti A; Terzolo M
    Endocr Relat Cancer; 2008 Dec; 15(4):1043-53. PubMed ID: 18824557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant mitotane in adrenocortical carcinoma.
    Bertherat J; Coste J; Bertagna X
    N Engl J Med; 2007 Sep; 357(12):1256-7; author reply 1259. PubMed ID: 17881760
    [No Abstract]   [Full Text] [Related]  

  • 7. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel.
    Berruti A; Fassnacht M; Baudin E; Hammer G; Haak H; Leboulleux S; Skogseid B; Allolio B; Terzolo M
    J Clin Oncol; 2010 Aug; 28(23):e401-2; author reply e403. PubMed ID: 20567001
    [No Abstract]   [Full Text] [Related]  

  • 8. Adjunctive treatment of adrenocortical carcinoma.
    Terzolo M; Berruti A
    Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):221-6. PubMed ID: 18438168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies.
    Demeure MJ; Somberg LB
    Surg Oncol Clin N Am; 1998 Oct; 7(4):791-805. PubMed ID: 9735134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.
    Fassnacht M; Hahner S; Polat B; Koschker AC; Kenn W; Flentje M; Allolio B
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4501-4. PubMed ID: 16895957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.
    Fassnacht M; Johanssen S; Fenske W; Weismann D; Agha A; Beuschlein F; Führer D; Jurowich C; Quinkler M; Petersenn S; Spahn M; Hahner S; Allolio B;
    J Clin Endocrinol Metab; 2010 Nov; 95(11):4925-32. PubMed ID: 20668036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant mitotane in adrenocortical carcinoma.
    Dickstein G; Shechner C; Nativ O
    N Engl J Med; 2007 Sep; 357(12):1257-8; author reply 1259. PubMed ID: 17891838
    [No Abstract]   [Full Text] [Related]  

  • 13. Mitotane treatment for adrenocortical carcinoma: an overview.
    De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
    Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma.
    Berruti A; Grisanti S; Pulzer A; Claps M; Daffara F; Loli P; Mannelli M; Boscaro M; Arvat E; Tiberio G; Hahner S; Zaggia B; Porpiglia F; Volante M; Fassnacht M; Terzolo M
    J Clin Endocrinol Metab; 2017 Apr; 102(4):1358-1365. PubMed ID: 28324035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
    Malandrino P; Al Ghuzlan A; Castaing M; Young J; Caillou B; Travagli JP; Elias D; de Baere T; Dromain C; Paci A; Chanson P; Schlumberger M; Leboulleux S; Baudin E
    Endocr Relat Cancer; 2010 Sep; 17(3):797-807. PubMed ID: 20592067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma.
    Gonzalez RJ; Tamm EP; Ng C; Phan AT; Vassilopoulou-Sellin R; Perrier ND; Evans DB; Lee JE
    Surgery; 2007 Dec; 142(6):867-75; discussion 867-75. PubMed ID: 18063070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant mitotane in adrenocortical carcinoma.
    Lee JE
    N Engl J Med; 2007 Sep; 357(12):1258; author reply 1259. PubMed ID: 17891836
    [No Abstract]   [Full Text] [Related]  

  • 18. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
    Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A
    Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.
    Postlewait LM; Ethun CG; Tran TB; Prescott JD; Pawlik TM; Wang TS; Glenn J; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem A; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Staley CA; Poultsides GA; Maithel SK
    J Am Coll Surg; 2016 Apr; 222(4):480-90. PubMed ID: 26775162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant mitotane therapy of adrenal cancer - use and controversy.
    Schteingart DE
    N Engl J Med; 2007 Jun; 356(23):2415-8. PubMed ID: 17554125
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.